Bryan Jones

Bryan Jones, PhD. has more than 30 years of experience with Biotech and Specialty Pharmaceutical companies with roles in both Product and Business Development. Prior to joining Aardvark, he was COO and Co-Founder of Sollis Therapeutics where he led the technology transfer from Medtronic, the manufacturing of a drug/device combination, and the execution of the Phase 3 Sciatica program. Prior to that, he was Vice President of Operations at Sorrento Therapeutics where he led the Resiniferatoxin program, including manufacturing, toxicology, and clinical planning as well as being involved in both monoclonal antibody production, ADC research, and cell therapy development. He has held roles of increasing responsibility including Chief Operating Officer of two startup companies: Sherrington and Mt. Cook. He has worked in Business Development at Amylin and Kemia. Earlier in his career, he worked in research at Bristol-Myers Squibb and on products such as Cialis® with ICOS. Dr. Jones received his PhD. in Genetics from the University of Washington and a Bachelor’s degree in Biology and Biochemistry from Iowa State University.